Enozertinib vs Neratinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR/HER2 · full Non-Small Cell Lung Cancer pipeline

Enozertinib

Developed by ORIC Pharmaceuticals under a licence from Voronoi, Inc

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06816992 (registry estimate)

No aligned efficacy figure on record for this race.

Neratinib

Marketed by Puma Biotechnology and partners

Phase 2 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01827267 · Phase 2 · completed

Patients were randomized between neratinib alone and neratinib plus temsirolimus, but the trial was open-label (unblinded) and each arm was small; the response-rate difference (0% vs 14%) was not accompanied by a reported statistical test, so whether adding temsirolimus produced a real benefit is unclear.

Reported efficacy

Objective Response Rate for Neratinib in Patients With Non-small Cell Lung Cancer (From first dose date to progression/death or last tumor assessment, up to three years.): Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response (missed)

Result source: NCT00266877

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnozertinibNeratinib
PFS, median—Not reported2.9bn 17NCT01827267
4 other results
OS, median—Not reported10bn 17NCT01827267
1 other result
ORR—Not reported3.3%bn 91NCT00266877
2 other results
Duration of response, median—Not reported12.5bn 3NCT00266877
1 other result

PFS, median

Enozertinib
—Not reported
Neratinib
2.9bn 17NCT01827267
4 other results

OS, median

Enozertinib
—Not reported
Neratinib
10bn 17NCT01827267
1 other result

ORR

Enozertinib
—Not reported
Neratinib
3.3%bn 91NCT00266877
2 other results

Duration of response, median

Enozertinib
—Not reported
Neratinib
12.5bn 3NCT00266877
1 other result
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Enozertinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Enozertinib: 0 of 4 rows · Neratinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNeratinib
Dropout rate
27.8%Neratiniba
NCT01827267 · Phase 2
show 4 more results
27.3%Neratinib+Temsirolimus
NCT01827267 · Phase 2 · combination
n/a: no completion milestoneNo Prior EGFR Tyrosine Kinase Inhi
NCT00266877 · Phase 2
n/a: no completion milestonePrior Tarceva or Iressa With EGFR
NCT00266877 · Phase 2
n/a: no completion milestonePrior Tarceva or Iressa w/o EGFR M
NCT00266877 · Phase 2
Discontinued due to AEs
—Neratiniba
NCT01827267 · Phase 2
show 4 more results
—Neratinib+Temsirolimus
NCT01827267 · Phase 2 · combination
3.6%No Prior EGFR Tyrosine Kinase Inhi
NCT00266877 · Phase 2
6.6%Prior Tarceva or Iressa With EGFR
NCT00266877 · Phase 2
8.3%Prior Tarceva or Iressa w/o EGFR M
NCT00266877 · Phase 2
Serious AEs
41.2%Neratiniba
NCT01827267 · Phase 2
show 4 more results
37.2%Neratinib+Temsirolimus
NCT01827267 · Phase 2 · combination
50%No Prior EGFR Tyrosine Kinase Inhi
NCT00266877 · Phase 2
36.3%Prior Tarceva or Iressa With EGFR
NCT00266877 · Phase 2
43.8%Prior Tarceva or Iressa w/o EGFR M
NCT00266877 · Phase 2
Most frequent reported AEs
a
diarrhoea 76.5%
constipation 41.2%
nausea 41.2%
NCT01827267 · Phase 2
show 4 more results
diarrhoea 86%
nausea 55.8%
decreased appetite 53.5%
NCT01827267 · Phase 2 · combination
diarrhoea 89.3%
nausea 57.1%
decreased appetite 39.3%
NCT00266877 · Phase 2
diarrhoea 93.4%
nausea 57.1%
abdominal pain 39.6%
NCT00266877 · Phase 2
diarrhoea 85.4%
nausea 50%
fatigue 39.6%
NCT00266877 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Neratinib

ORR 0% (n=17)
event count · % of participants
No placebo or comparator arm
NCT01827267 · Phase 2 · converted to % from 0 Participants as posted
show 1 more result
14% (n=43)*
NCT01827267 · Phase 2 · combination · converted to % from 6 Participants as posted
Clinical Benefit 35.3% (n=17)
event count · % of participants
No placebo or comparator arm
NCT01827267 · Phase 2 · converted to % from 6 Participants as posted
show 1 more result
48.8% (n=43)*
NCT01827267 · Phase 2 · combination · converted to % from 21 Participants as posted
PFS 2.9 months
time to event · months
No placebo or comparator arm
NCT01827267 · Phase 2
show 4 more results
4 months
NCT01827267 · Phase 2 · combination
3.53 months*
NCT00266877 · Phase 2 · converted to months from 15.3 weeks as posted
3.72 months*
NCT00266877 · Phase 2 · converted to months from 16.1 weeks as posted
2.15 months*
NCT00266877 · Phase 2 · converted to months from 9.3 weeks as posted
Overall Survival 10 months
time to event · months
No placebo or comparator arm
NCT01827267 · Phase 2
show 1 more result
15.1 months
NCT01827267 · Phase 2 · combination
ORR 3.3% (n=91)
responder rate · % of participants
No placebo or comparator arm
NCT00266877 · Phase 2
show 2 more results
0% (n=48)
NCT00266877 · Phase 2
3.6% (n=28)
NCT00266877 · Phase 2
Clinical Benefit 9.9% (n=91)
responder rate · % of participants
No placebo or comparator arm
NCT00266877 · Phase 2
show 2 more results
6.3% (n=48)
NCT00266877 · Phase 2
10.7% (n=28)
NCT00266877 · Phase 2
Duration of Response 12.48 months
time to event · months
No placebo or comparator arm
NCT00266877 · Phase 2 · converted to months from 54.1 weeks as posted
show 1 more result
6.62 months*
NCT00266877 · Phase 2 · converted to months from 28.7 weeks as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enozertinib's landscape · Neratinib's landscape